Cargando…

Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripher...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peng, Yi, Shuhong, Li, Xi, Liu, Ruilei, Jiang, Hua, Huang, Zenan, Liu, Yu, Wu, Juekun, Huang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103844/
https://www.ncbi.nlm.nih.gov/pubmed/25036145
http://dx.doi.org/10.1371/journal.pone.0102197
_version_ 1782327203972775936
author Zhang, Peng
Yi, Shuhong
Li, Xi
Liu, Ruilei
Jiang, Hua
Huang, Zenan
Liu, Yu
Wu, Juekun
Huang, Yong
author_facet Zhang, Peng
Yi, Shuhong
Li, Xi
Liu, Ruilei
Jiang, Hua
Huang, Zenan
Liu, Yu
Wu, Juekun
Huang, Yong
author_sort Zhang, Peng
collection PubMed
description Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG(2). Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy.
format Online
Article
Text
id pubmed-4103844
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41038442014-07-21 Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells Zhang, Peng Yi, Shuhong Li, Xi Liu, Ruilei Jiang, Hua Huang, Zenan Liu, Yu Wu, Juekun Huang, Yong PLoS One Research Article Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG(2). Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy. Public Library of Science 2014-07-18 /pmc/articles/PMC4103844/ /pubmed/25036145 http://dx.doi.org/10.1371/journal.pone.0102197 Text en © 2014 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhang, Peng
Yi, Shuhong
Li, Xi
Liu, Ruilei
Jiang, Hua
Huang, Zenan
Liu, Yu
Wu, Juekun
Huang, Yong
Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
title Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
title_full Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
title_fullStr Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
title_full_unstemmed Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
title_short Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
title_sort preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103844/
https://www.ncbi.nlm.nih.gov/pubmed/25036145
http://dx.doi.org/10.1371/journal.pone.0102197
work_keys_str_mv AT zhangpeng preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells
AT yishuhong preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells
AT lixi preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells
AT liuruilei preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells
AT jianghua preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells
AT huangzenan preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells
AT liuyu preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells
AT wujuekun preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells
AT huangyong preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells